UNSPSC 51384611: Feprazone

This classification denotes a cyclooxygenase inhibitor with the molecular formula C20H20N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7BVX6J0CGR, chemically known as 3,5-pyrazolidinedione, 4-(3-methyl-2-butenyl)-1,2-diphenyl- but generally known as feprazone, which bears US NIH Compound Identifier 35455. European Medicines Agency schedules Feprazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07607MIG.

UNSPSC 51384611 Feprazone is a Commodity code that designates a specific pharmaceutical product, but recent state and local solicitations tagged with this code do not actually procure feprazone itself. Instead, issuing bodies are buying naloxone, drug deactivation systems, generic multi-source pharmaceuticals, over-the-counter products, and exploring direct-to-manufacturer prescription fulfillment models. State and local governments purchasing under this code span county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple jurisdictions. The work involves bulk procurement of finished pharmaceutical goods and ancillary health-supply items, with vendors required to manage logistics, maintain cGMP and FDA compliance certifications, carry specified insurance coverage (including commercial general liability ranging from $2 million to $5 million per occurrence), and in some cases establish direct contracts with state agencies outside traditional pharmacy benefit manager and group purchasing organization channels.

Recent activity concentrates in Florida and Minnesota. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, requesting 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, Florida, with bids due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026, and contract awards effective July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer prescription programs without traditional intermediaries. Vendors should note that this code shows significant mismatch between its nominal pharmaceutical designation and the actual scope of work solicited; recent opportunities emphasize operational logistics, compliance certifications, and wholesale distribution relationships rather than the branded drug product itself.